PRECIGEN, INC. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PRECIGEN, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-12-31 was $0.00.
- PRECIGEN, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2025-09-30 was $209.88M.
- PRECIGEN, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2020-12-31 was $25.00M.
- PRECIGEN, INC. stock issued during period, value, conversion of convertible securities for the quarter ending 2020-09-30 was $31.83M.
- PRECIGEN, INC. stock issued during period, value, conversion of convertible securities for fiscal 2025 was $209.88M.
- PRECIGEN, INC. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $56.83M.
- PRECIGEN, INC. stock issued during period, value, conversion of convertible securities for fiscal 2013 was $571.90M.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $209.88M 10-K · filed 2026-03-25 |
| 2025-09-30 | $209.88M 10-Q · filed 2025-11-13 | |
| 2020-12-31 | $25.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $56.83M 10-K · filed 2023-03-06 |
| 2020-09-30 | $31.83M 10-Q · filed 2021-11-08 | |
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $571.90M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |